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ARTICLE
Multiple Forms of Cardiac Myosin-binding Protein C Exist 
and Can Regulate Thick Filament Stability
Irina Kulikovskaya, George B. McClellan, Rhea Levine, and Saul Winegrad
Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104
Although absence or abnormality of cardiac myosin binding protein C (cMyBP-C) produces serious structural and 
functional abnormalities of the heart, function of the protein itself is not clearly understood, and the cause of the 
abnormalities, unidentifi  ed. Here we report that a major function of cMyBP-C may be regulating the stability of the 
myosin-containing contractile fi  laments through phosphorylation of cMyBP-C. Antibodies were raised against 
three different regions of cMyBP-C to detect changes in structure within the molecule, and loss of myosin heavy 
chain was used to monitor degradation of the thick fi  lament. Results from Western blotting and polyacrylamide gel 
electrophoresis indicate that cMyBP-C can exist in two different forms that produce, respectively, stable and un-
stable thick fi  laments. The stable form has well-ordered myosin heads and requires phosphorylation of the cMyBP-C. 
The unstable form has disordered myosin heads. In tissue with intact cardiac cells, the unstable unphosphorylated 
cMyBP-C is more easily proteolyzed, causing thick fi  laments fi  rst to release cMyBP-C and/or its proteolytic peptides 
and then myosin. Filaments defi  cient in cMyBP-C are fragmented by shear force well tolerated by the stable form. 
We hypothesize that modulation of fi  lament stability can be coupled at the molecular level with the strength of 
contraction by the sensitivity of each to the concentration of calcium ions.
INTRODUCTION
Although absence or abnormality of myosin binding 
protein C (cMyBP-C) from the hearts of rodents and 
humans produces structural abnormalities (cardiac 
  hypertrophy and dilatation, patchy myofi  brillar disar-
ray, and fi  brosis) and serious dysfunction (reduced car-
diac ejection, impaired diastolic fi  lling, and reduced 
capacity to function with increased load) (Bonne et al., 
1995; Rottbauer et al., 1997; Charron et al., 1998; 
Niimura et al., 1998; Yang et al., 1998, 2001; McConnell 
et al., 2001; Harris et al., 2002; Sadayappan et al., 2005, 
2006), function of cMyBP-C is not clearly under  stood, 
and the cause of the abnormalities, unidentifi  ed (Watkins 
et al. 1995). One cMyBP-C consists of 11 domains 
or modules labeled C0 to C10 from N to C terminus 
(Fig. 1). Near its C terminus, cMyBP-C has binding sites 
for titin and the myosin rod, and at the N-terminal re-
gion, binding sites for actin (Kulikovskaya et al., 2003a; 
Squire et al., 2003; Herron et al., 2006) and the S2 frag-
ment of myosin (Kunst et al., 2000). Three molecules of 
cMyBP-C are localized every 43 nm in the C zone of the 
sarcomere (Craig and Offer, 1976). Modules C5–C10 
from the three molecules appear to interact, possibly 
resulting in a transverse “collar” around the thick fi  lament 
that stabilizes the fi  lament’s structure (Moolman-Smook 
et al., 2002; McClellan et al., 2004). Three phosphory-
lation sites exist between modules C1 and C2, and 
the degree of phosphorylation determines whether the 
N-terminal region binds to myosin or actin (Hartzell 
and Glass, 1984; Schlender and Bean, 1991; Gautel et al., 
1995; Kulikovskaya et al., 2003a). Dephosphorylation of 
cMyBP-C changes the structure of cardiac thick fi  lament, 
resulting in a shift of myosin heads from well-ordered 
positions along the backbone of the fi  lament to a disor-
dered array extending from the backbone (Weisberg 
and Winegrad, 1996, 1998; Levine et al., 2001). Either 
Ca-calmodulin–activated kinase (CAMK) or PKA can 
phosphorylate isolated cMyBP-C (Schlender and Bean, 
1991; McClellan et al., 2001; Gautel et al., 1995), but 
in intact cardiac muscle, isoproterenol can produce 
phosphorylation only if the fi  rst phosphate is already 
present (McClellan et al., 2001).
Cessation of contraction of intact cardiac trabeculae 
reversibly reduces maximum Ca-activated force (Fmax) 
and actomyosin ATPase activity while maximum un-
loaded shortening velocity remains unchanged (Lin 
et al., 1991). This suggests that the number of cycling 
force generators can be modifi  ed by contractile activity. 
The reduction can be reversed by any of several meth-
ods each of which increases intracellular Ca concentra-
tion and may also phosphorylate myofi  brillar proteins. 
The only myofi  brillar phosphorylation that consistently 
followed the change in force and ATPase activity in di-
rection and amplitude was that of cMyBP-C (McClellan 
et al., 1994).
R. Levine died on 18 January 2002.
Correspondence to Saul Winegrad: bsg@mail.med.upenn.edu
Abbreviations used in this paper: CAMK, Ca-calmodulin–activated 
kinase; cMyBP-C, cardiac myosin binding protein; TNT, tropomyosin 
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The rate of degradation of myosin in rhythmically 
contracting, cultured neonatal ventricular cells is closely 
related to the concentration of Ca in the extracellular 
space (Byron et al., 1996). The rate of degradation moves 
inversely with the concentration of Ca. The site of action 
of the Ca is intracellular because Ca channel blockade 
increases the rate of degradation. Ca does not appear to 
exert its effect on degradation of myosin by altering ten-
sion development. The addition of 2,3-  butanedione 
monoxime, which inhibits development of Ca-activated 
tension in striated muscle (Zhao et al., 1995), does not 
prevent the effect of Ca on the rate of degradation. 
Stimulated by the results of Byron et al. (1996), we have 
tested the hypothesis that cMyBP-C and its phosphoryla-
tion modulate the stability of the myosin-containing 
thick fi  laments. These studies have been conducted on 
wild-type (WT) rat hearts in order to   investigate the 
function of cMyBP-C in the normal heart.
MATERIAL AND METHODS
Antibodies
Polyclonal antibodies raised against recombinant C0C1, C0C2, 
C5, and C8C9, (Fig. 1 and Fig. 2 A) produced from human cDNA 
encoding cardiac MyBP-C (cMyBP-C). The antibodies were tested 
for specifi  city against lysed rat cardiac ventricle that had been 
quickly frozen immediately after the chest had been opened. This 
tissue was chosen because it most closely resembled the in vivo 
state of the heart. The tissue was lysed and electrophoresed on 
polyacrylamide gels, and three Western blots were prepared using 
each of the different antibodies against cMyBP-C (McClellan et al., 
2004). A single band was present at 145 kD in each blot of the 
quickly frozen muscle (Fig. 2 A).
Phosphorylation of cMyBP-C
PKA-mediated phosphorylation of MyBP-C was measured using 
an antibody against phosphorylated PKA substrate sites (Cell 
  Signaling Technology phospho-serine/threonine substrate anti-
body #2851; referred in text as anti-phosphate). The antibody rec-
ognizes PKA substrate that has already been phosphorylated. 
Appropriate controls established that cMyBP-C was specifi  cally 
stained by the antibody. Although CAMK normally adds the fi  rst 
phosphate to cMyBP-C in the intact fi  lament lattice (Hartzell and 
Glass, 1984; Schlender and Bean, 1991; McClellan et al., 2001), 
PKA can add the fi  rst phosphate to isolated cMyBP-C and to the 
C1C2 fragment that contains the phosphorylation sites (Gautel 
et al., 1995). On denaturing gels, the antibody against PKA-
  phosphorylated sites recognizes mono-, di-, and triphosphorylated 
cMyBP-C (not depicted). Therefore it recognizes the CAMK-
mediated phosphorylated site under these conditions. The absence 
of staining with the antibody on Western blots means that none of 
the three phosphorylateable sites was actually phosphorylated.
Skinned Trabeculae
Treatment of animals in all studies was in accordance with the 
guidelines of the University of Pennsylvania Animal Care Com-
mittee. All experiments were conducted at room temperature, 
20–22°C. Trabeculae were chemically skinned with 1% Triton 
X-100 in a relaxing solution using solutions and protocols already 
described (Lin et al., 1991). The skinning solution was washed 
out with several changes of relaxing solution over 30 min. 
All   solutions were collected and analyzed by SDS-PAGE followed by 
Western blotting with antibodies against cMyBP-C and MHC. 
  Neither protein was found in either the skinning or the washout 
solutions with this sensitive technique.
Resistance to Shear Force
A solution of isolated thick fi  laments was passed through a capil-
lary tube of measured diameter and length under a measured 
pressure. The shear force was calculated from the dimensions of 
the tube and the pressure. As the aim of this part of the study was 
to determine if loss of cMyBP-C altered the resistance of thick fi  la-
ments to shear force, the study was conducted at only two levels of 
shear force covering a range of 2–3-fold.
Isolated Thick Filaments, Western Blots, IEF Gels
The methods for isolating thick fi  laments and preparing IEF gels 
and Western blots have been described in detail (Weisberg and 
Winegrad, 1996; Levine et al., 2001).
Data Analysis
The density of individual bands in gels and Western blots was de-
termined by scanning densitometry and the NIH Image program 
(Fig. 2, A–C). Calibration curves for the density produced by 
cMyBP-C stained with each of the three antibodies were gener-
ated using different amounts of purifi  ed cMyBP-C and different 
amounts of the lysate of quickly frozen cardiac muscle (Fig. 2). 
The curves were the same nonlinear power functions with the 
two methods.
Tropomyosin binding subunit of troponin (TNT) was present 
in every sample of cardiac muscle and was not altered by the pro-
tocols employed in this study (see Fig. 8). When the same amount 
of protein from lysates of heart muscle was loaded on gels, the 
density of the TNT band was highly reproducible. These prop-
erties made TNT an excellent candidate protein for normaliza-
tion of the cMyBP-C bands and quantitating changes in the amount 
of cMyBP-C.
Equal amounts of protein from experimental and control 
hearts were loaded on the lanes of gels. The ratio of the densities 
of the cMyBP-C to the TNT band from experimental tissue was 
compared with the ratio under control conditions (quickly frozen 
cardiac muscle). Deviations from the control ratio indicated an 
  effect of the experimental protocol on the amount of cMyBP-C. 
The   effect was quantifi  ed by determining the correct position for 
the control and experimental densities on the calibration curve. 
Figure 1.  Diagram of cMyBP-C indicating modules, interactions 
with actin, myosin, and titin and interactions between modules. 
Location of phosphorylation sites is shown.  Kulikovskaya et al. 421
With control tissue, the density on the curve for cMyBP-C equaled 
the actual measured density of the cMyBP-C band when the stan-
dard amount of protein was loaded on the gel. The amount of 
protein was chosen to place the density on the relatively linear 
portion of the calibration curve. Provided the measured densities 
of TNT from the control and the experimental tissues were the 
same (as they normally were), the correct position on the calibra-
tion curve for the density of cMyBP-C from the experimental tis-
sue was the actual measured density on the gel. In this way the 
difference between the control and experimental amounts of 
cMyBP-C was determined, and possible confounding effects of 
the nonlinearity of the calibration curve were eliminated. All 
quantitative values given in the Results have been normalized in 
this way.
TNT was not present in the washout of skinned trabeculae and 
therefore could not be used for normalization in measurements 
of cMyBP-C and myosin heavy chain (MHC) in these solutions. 
The amount of the washouts applied to the lanes of the gel was set 
so that the amount of cMyBP-C or MHC produced a density simi-
lar to those of our standard control on the same gel. The relative 
amounts of cMyBP-C and MHC were determined from the cali-
bration curves.
Staining and conditions for exposure of the fi  lm to the gel were 
kept constant.
Statistics
Statistical signifi  cance was determined by the Student’s t test and 
ANOVA, with P < 0.05 considered to be signifi  cant. Where 
  appropriate, the Bonferroni correction was made.
RESULTS
Multiple forms of cMyBP-C in the whole animal
Western blots of lysed rat ventricle quickly frozen imme-
diately after euthanasia were produced using antibodies 
against C0C2, C5 and C8C9 fragments of cMyBP-C. Each 
blot had a dense band with an apparent molecular 
weight of 145 kD (Fig. 2 A) and, in some cases, a faint 
suggestion of a band at 130 kD in the anti-C5 and anti-
C8C9 blots (Fig. 3). During euthanasia of a rat there is a 
large release of catecholamines that increases phosphor-
ylation of cMyBP-C. This release of catecholamines can 
be blocked by intraperitoneal injection of the β adrener-
gic blocker, propranolol. When 10 μg/kg of proprano-
lol was injected into the peritoneal cavity 20 min before 
euthanasia to block the action of the catecholamine, 
Western blots with anti-C5 and anti-C8C9 produced two 
clear, separate bands, one at 145 kD and a second at 130 
kD (Fig. 3). There was no staining of a 130-kD band with 
anti-C0C2. The density of the single 145-kD band stained 
with anti-C0C2 was signifi  cantly reduced by the propran-
olol injection, suggesting that some cMyBP-C existed in 
a form not stained by that antibody. In every one of 17 
experiments the second band disappeared after washing 
out the propranolol and incubating the intact trabecula 
in 0.1 μM isoproterenol for 15 min (Fig. 3). These re-
sults indicate that under normal physiological condi-
tions two different forms of cMyBP-C under adrenergic 
control can exist in vivo and the conversion of one to the 
other can occur within minutes.
Beta adrenergic agonists cannot cause phosphoryla-
tion of cMyBP-C in intact cardiac cells unless one phos-
phate is already present (McClellan et al., 2001). A similar 
restriction exists on the conversion of the 130- to the 
145-kD form by β adrenergic agonists. 0.1 μM isoproter-
enol was added to the bathing solutions of trabeculae 
that had been soaked in 1.0 or 2.5 mM Ca for 2 h to pro-
duce, respectively, low and moderately high levels of pho  s-
phorylated cMyBP-C (McClellan et al., 2001). The drug 
increased the density of the 145-kD band where a major 
Figure 2.  (A) Western blots showing the specifi  city of antibodies 
against of cMyBP-C fragments. The antibodies were tested against 
the lysate of a piece of ventricle rapidly frozen as soon as the chest 
had been opened. (B) Blots using anti-C5 with different amounts 
of lysate of quickly frozen heart. Lanes 1–4 contain 1, 4, 10, and 
20 relative amounts of protein. (C) Calibration curve of cMyBP-C. 
Each point represents the mean of at least fi  ve muscles. Dose–
  response plots using anti-C0C2 and anti-C8C9 (not depicted) 
were very similar to the relation using anti-C5.
Figure 3.  Western blots of rat heart using three antibodies. Lane 1, 
quickly frozen tissue from a heart of a control animal (had not 
received propranolol); lane 2, quickly frozen tissue from a heart 
that had received propranolol before euthanasia; and lane 3, 
quickly frozen tissue from heart of an animal that had received 
propranolol before euthanasia, and after removal from the heart 
had been soaked in propranolol-free medium for 15 min followed 
by medium with 0.1 μM isoproterenol for 15 min.422 Myosin-binding Protein C and Contractile Filament Turnover
fraction (>60%) of cMyBP-C was phosphorylated before 
the addition of the drug and had much less effect where 
only a minor fraction of the cMyBP-C (<20%) was phos-
phorylated (unpublished data).
The 130-kD protein was not a proteolytic fragment of 
cMyBP-C. The N-terminal sequence of the 130-kD band 
(P  E  P  G  K  R  P  V  S  A  ), identifi  ed by Edman degradation, was 
the same as the sequence in human, mouse, and dog 
cMyBP-C except for substitution of arginine for lysine 
at position 6, both of which carry a negative charge (xPASy 
database). It was not possible to sequence the N ter-
minus of the 145-kD band because the protein appeared 
to be blocked to Edman degradation. Proteolysis of C10 
and/or C9 at the C terminus was an unlikely cause 
of the more rapid migration on the gel because of the 
following: (a) anti-C8C9 still recognized the 130-kD 
form and anti-C0C2 did not; (b) rapid reversibility of 
the migration pattern; and (c) the rapid change in den-
sity of the 145- and 130-kD bands after exposure to iso-
proterenol. The increase in the density of the 145-kD 
bands and the decrease of the 130-kD bands occurred 
too rapidly for in vitro protein synthesis. Restoration of 
cMyBP-C after the proteolysis that occurs during tran-
sient ischemia requires  10 d (Decker et al., 2005). 
Very small changes in a protein can produce changes in 
its rate of migration on SDS gels that normally would 
indicate a larger change in molecular weight (Bottinelli 
et al., 1998; Katori et al., 2004). This is particularly true 
of phosphorylation (Burden and Sullivan, 1994).
Effect of [Ca] on the two forms of cMyBP-C
The density of both bands in gels from resting trabecu-
lae varied with the concentration of Ca in the super-
fusion solution and the duration of incubation (Figs. 
4 and 5; n = 16; P < 0.05). Trabeculae frozen within 
3 min of euthanasia produced the same single band as 
quickly frozen ventricles. After 2 or more hours at rest 
Figure 4.  Western blots with three antibodies against different 
regions of cMyBP-C. The protocols (duration of soak and Ca con-
centration) for the various muscles are shown. Note the single 
bands with quickly frozen trabeculae, and the second band with 
antibodies against C8C9 and C5. The second band is not present 
when the bathing solution contained 7.5 mM Ca. The density of 
the second band increases over the fi  rst 3 h in 1.0 mM Krebs’ solu-
tion and then gradually becomes less dense. Note the reproduci-
bility in lanes 2 and 3.
Figure 5. (A)  Densities of 145- and 130-kD forms plotted as a function of the duration of incubation of the trabeculae in 1.0 or 7.5 mM Ca. 
Each point represents the mean ± SEM of at least fi  ve experiments. The antibody against C5 was used in the Western blots. Results with 
the antibody against C8C9 were not statistically different (not depicted). Lines between points are interpolations and do not represent 
a specifi  c function. Open circles 145 kD in 7.5 mM Ca, open squares 130 kD in 7.5 mM Ca, fi  lled circles 145 kD in 1.0 mM Ca, and fi  lled 
squares 130 kD in 1.0 mM Ca. Asterisk indicates statistical signifi  cance from 1.5 h. (B) Plot of combined densities of 145- and 130-kD 
forms as a function of the duration of the incubation in electrolyte solution with 1.0, 2.5, or 7.5 mM Ca. Asterisks indicate signifi  cant dif-
ference from value at 3 h. Lines between points are interpolations and do not represent a specifi  c function. Filled circles 145+130 kD 
in 1.0 mM Ca, fi  lled squares 145+130 kD in 2.5 mM Ca, and open squares 145+130 kD in 7.5 mM Ca. (C) Comparison of peptides 
in lysates stained with each antibody after 4 h incubation in 1.0 mM Ca. Density of TNT bands after SDS-PAGE, stained with a specifi  c 
antibody and used for normalization, was the same in all three lanes (not depicted). Note the larger number of peptides stained with 
anti-C0C2 than with either anti-C5 or anti-C8C9.  Kulikovskaya et al. 423
in 1.0 mM Ca (during which bound catecholamine was 
washed out), Western blots of trabeculae produced the 
same bands as hearts from propranolol-injected ani-
mals. Trabeculae soaked at rest in 7.5 mM Ca for up to 
6 h had little or no 130-kD form and a constant density 
of their 145-kD form (Fig. 4). Decreasing Ca concentra-
tion from 7.5 to 1.0 mM produced a 130-kD band and 
decreased the 145-kD band. Raising Ca from 1.0 to 7.5 
inhibited further change in the two bands, but it did 
not signifi  cantly reverse the changes that had already 
occurred in 1.0 mM (n = 4, P < 0.05).
Density of both bands changed with the duration of the 
exposure to 1.0 mM Ca (Figs. 4 and 5). For 3 h the density 
of the 130- and 145-kD forms, respectively, increased and 
decreased, but the combined densities remained constant 
(Fig. 5 A). The intensity of the 130-kD band increased 
to a peak at 3 h, and then declined with further superfu-
sion (Fig. 5). After 3 h, the combined densities decreased 
(Fig. 5 B). 2.5 mM Ca produced a similar course, but the 
magnitude of the changes was smaller.
Proteolysis of the 130-kD Form of cMyBP-C
The sum of densities of the 145- and 130-kD forms re-
mained constant for 3 h regardless of the Ca concentra-
tion in the soak solution (Fig. 5 A). After >3 h in 1 mM 
Ca, the amount of the 130 kD and the sum of the two 
densities gradually decreased (Fig. 5 B). Initially the 
145 kD was converted to the 130-kD form, but after 3 h, 
proteolysis of the 130-kD form became apparent. Lower 
molecular weight bands stained by the antibodies against 
cMyBP-C appeared (Fig. 5 C). Most of the visible smaller 
peptides were stained by anti-C0C2 and not by anti-C5 
or -C8C9, indicating that the proteolysis was pro  bably 
occurring in the C5 to C10 region, which forms a puta-
tive collar around the thick fi  lament.
The ability of anti-C0C2 to stain proteolytic fragments 
of the 130-kD form of cMyBP-C supports the conclusion 
from sequencing that the N-terminal region has not been 
lost in the conversion of the 145- to the 130-kD form. The 
proteolysis in the C5C9 region has apparently had an ef-
fect on the epitope in the C0C2 region enhancing the 
recognition of the protein by the anti-C0C2, consistent 
with other data that events in one end of the molecule can 
infl  uence the nature of the other end of the molecule 
(McClellan et al., 2004).
Differences in Phosphorylation in the Two Forms 
of cMyBP-C
Anti-phosphate antibody measures total phosphate and 
can  not distinguish among the three phosphorylation 
sites. The antibody always stained the 145-kD band and 
with one exception never stained the 130-kD band (Fig. 6). 
The extent of antiphosphate antibody staining varied 
considerably depending on prior treatment. Incubation 
with 7.5 mM Ca, which prevented the appearance of the 
130-kD band, was associated with a high level of phos-
phorylation. A 2-h soak in 1 mM Ca reduced antiphos-
phate staining by >50%.
Incubation with 10 U of alkaline phosphatase for 4 h 
reduced phosphorylation to an undetectable level and 
converted all of the 145-kD form to the 130-kD form (Fig. 
6, B and C). Incubation with 3 U decreased the phos-
phate content of cMyBP-C by 64 ± 7% (n = 4, P < 0.05), 
and converted 23 ± 4% (n = 4, P < 0.05) of the 145- to 
the 130-kD form. After incubation of a preparation hav-
ing a low level of phosphorylation of cMyBP-C (as a result 
of incubation in a 1.0 mM Ca solution) with PKA, the 
level of phosphorylation and the relative amount of the 
145-kD form were increased substantially (Fig. 6 D).
Effect of Contraction on the Two Forms of cMyBP-C
After 3 h of superfusion at rest in 2.5 mM Ca, several 
trabeculae were stimulated for 30 min at 12 Hz. The 
stimulation, which would be expected to raise time-
  averaged concentration of intracellular Ca, increased 
  antiphosphate staining of the 145-kD band by 42 ± 6% 
(P < 0.05; n = 5), and produced the only detectable 
staining of the 130-kD band. A portion of the 130-kD 
band was converted to the 145-kD band. The relative 
  intensity of the 145-kD band increased by 37 ± 5% 
Figure 6.  (A) Blots of antibody against C5 (bottom) and phosphor-
ylated PKA substrate (top). The same gel is shown. Lane 1, quickly 
frozen; lane 2, 4 h in 1.0 mM Ca; lanes 3 and 4, stimulated at 12/min 
for 30 min in 2.5 mM Ca after 3 h at rest in 2.5 mM Ca; lane 5, 
soaked for 5 h in 7.5 mM Ca. The 130-kD band is absent from the 
anti-PKA substrate Western except where the trabecula was rhyth-
mically contracting (lanes 3 and 4). (B) The effect of total dephos-
phorylation on the conversion of the 145- to the 130-kD form. 
Western blots with anti-C8C9 (lanes 1–5) of lysed cardiac muscle 
that had been quickly frozen. In lane 5, the same lysate has been 
incubated with 10 U alkaline phosphatase for 4 h. Lane 1, alkaline 
phosphatase buffer (Promega); lane 2, urea-thiourea-CHAPS 
(UTC) lysate; lane 3, pellet in lithium dodecyl sulfate; lane 4, UTC 
lysate; lane 5, UTC lysate (same as lane 1) incubated at 37°C for 4 h 
with calf intestinal phosphatase (Promega). Marker on left is 
150 kD. (C) Shows the same proteins after incubation with anti-PKA 
substrate phosphate. (D) Phosphorylation converts 130- to 145-kD 
form. Controls are isolated thick fi  laments prepared from of trabec-
ula soaked for 2 h in 1.0 mM Ca to dephosphorylate cMyBP-C. PKA 
are thick fi  laments from same preparation exposed to 30 U of the 
catalytic subunit of PKA for 90 min. Western blots were stained with 
anti-C5 and the anti-PO4 with antiphosphate antibody.424 Myosin-binding Protein C and Contractile Filament Turnover
(n = 5, P < 0.05) and the intensity of the 130-kD band 
decreased (Fig. 6 A). Since it was not possible to stimu-
late isolated trabeculae at in vivo rates, we could not as-
certain whether physiological rates of stimulation would 
produce greater phosphorylation and transition between 
the two forms.
Ultrastructure of Thick Filaments
Isolated, negatively stained thick fi  laments had different 
structures depending on which form of cMyBP-C was 
predominant (Fig. 7). Populations of predominately 
the 130- or the 145-kD form were produced by using, 
  respectively, 1.0 or 7.5 mM Ca in the soak solutions. 
Thick fi  laments with the 130-kD form had disordered 
myosin heads that were often extended at different angles 
to the fi  lament backbone (Fig. 7 A). With the 145-kD 
form, myosin heads were well ordered, lying uniformly 
along the backbone of the fi  lament (Fig. 7 B).
Loss of MHC Follows Loss of cMyBP-C
Trabeculae were chemically skinned to permit control 
of the microenvironment of the myofibrils, to detect 
changes in the composition of the contractile fi  laments, 
and to determine whether the cMyBP-C or its proteolytic 
fragments were bound to myofi  brils. Bound protein re-
mained with the skinned cardiomyocytes while pro-
tein not bound in the cell interior appeared in the 
soak solution.
After dissection, intact resting trabeculae were soaked 
in electrolyte solution containing either 1.0 or 7.5 mM Ca 
for 2 h to produce cells with respectively low (<20%) 
and high (>80%) levels of phosphorylation of cMyBP-C. 
During and immediately after their skinning, there was 
no loss of myosin or cMyBP-C in the several bathing 
solutions, indicating that no cMyBP-C or MHC had 
been removed from the trabeculae. 4 h after skinning, the 
relaxing solution that had bathed trabeculae from the 
7.5 mM Ca group contained 3 ± 0.4% of the total 
cMyBP-C (P < 0.05) and 1% of myosin heavy chain 
(MHC; P > 0.05; the reference value for 100% protein 
was the total amount of each protein in trabeculae after 
their skinning). There was no statistically significant 
change in the cMyBP-C or MHC content of the trabeculae. 
Over the same period in relaxing solution, trabeculae 
from the 1.0 mM Ca group lost signifi  cantly more 
cMyBP-C and MHC, respectively, 18 ± 3% cMyBP-C and 
6 ± 2% MHC (n = 6; P < 0.05). These washouts of 
cMyBP-C and MHC were accompanied by signifi  cant 
declines in the content of cMyBP-C and MHC in the 
trabeculae of, respectively, 23 ± 5 and 8 ± 4% (P < 
0.05). The total cMyBP-C lost may have been under-
estimated by this method because washout solutions 
contained low molecular weight peptides stained by 
antibodies against regions of cMyBP-C. TNT was not 
present in any soak solutions, indicating that the insta-
bility was limited to the thick fi  lament (Fig. 8).
After extraction of  20% of the total cMyBP-C, release 
of MHC began (Fig. 9 A). Release of MHC always fol-
lowed, never preceded or accompanied, the initial ex-
traction of cMyBP-C (Fig. 9 B). Thick fi  lament stability 
appeared to exist until the fi  laments had lost at least 
20% of cMyBP-C. The rate at which cMyBP-C was ex-
tracted was faster when the trabeculae had been exposed 
to 1.25 mM than to 2.5 or 7.5 mM Ca, but the threshold 
of cMyBP-C loss at which the loss of MHC began was not 
signifi  cantly different.
Isolated thick fi  laments were much less resistant to 
shear forces after a large fraction of cMyBP-C has been 
extracted (Kulikovskaya et al., 2003b). Filaments with 
35% of cMyBP-C extracted (using the protocol of 
Kulikovskaya et al., 2003b) began to fragment at  17 
dynes/cm2. Thick fi  laments with a normal complement 
of cMyBP-C were able to withstand shear forces at least 
two to three times higher without fragmenting (Fig. 10). 
The length of the fragments varied from over 0.8 μm 
to the dimensions of individual double-headed myo-
sin molecules.
Thick fi  laments were isolated from trabeculae that 
had been bathed at rest for 2 h in 1.25 mM Ca solutions 
to produce a low level of phosphorylation of cMyBP-C 
Figure 7.  Electron micrographs of a part of two isolated thick 
  fi  laments. (A) From a trabecula that had been soaked in 1.0 mM 
Ca to produce dephosphorylated cMyBP-C and a band at 130 kD 
with anti-C5 or anti-C8C9. Arrowheads point to irregular,  extended 
myosin heads. (B) From a trabecula that had been soaked in 
7.5 mM Ca to produce phosphorylated cMyBP-C and prevent 
a band at 130 kD with anti-C5 or anti-C8C9. Arrows point to 
regular myosin heads lying along fi  lament backbone. Line indi-
cates 70 nm.
Figure 8.  Western blot of soak solutions from skinned trabeculae 
using anti-TNT. Lane 1, relaxing solution after 4 h; lane 2, relax-
ing solution after 18 h; lane 3, lysate of relaxed trabecula after 
4 h; lane 4, contraction solution used 3 times; lane 5, relaxing so-
lution used for 3 h between contractions; lane 6, relaxing solution 
used for 15 h after three series of contraction solutions; lane 7, 
lysate of trabecula that had contracted. The entire incubation 
solution was concentrated for use in the blot, but only 1/3 of 
the lysate was used in the blot.  Kulikovskaya et al. 425
(McClellan et al., 2001; Kulikovskaya et al., 2003b) and 
then subjected to the same level of shear force as ex-
tracted filaments. These thick filaments fragmented 
into pieces that were similar to those in the preparation 
of extracted fi  laments. As only a limited range of shear 
force was used, it was not possible to determine whether 
dephosphorylation of cMyBP-C produces the same de-
gree of fi  lament instability as extraction. (This point is 
currently being studied using a more quantifi  ed level of 
shear force and a larger population of thick fi  laments.)
DISCUSSION
Multiple Forms of cMyBP-C
In the intact heart in vivo, cMyBP-C can exist in at least 
two different forms, identifi  able from the different mi-
gration on SDS gels and the different binding patterns 
of antibodies. One is phosphorylated, relatively resis-
tant to proteolysis, and associated with greater stability 
of thick fi  laments (145-kD form). The other is unphos-
phorylated, relatively sensitive to protease, and associ-
ated with lower stability of thick fi  laments (130-kD form). 
Different electron micrograph images of thick fi  laments 
with the two different forms of cMyBP-C were observed. 
In the presence of the 145-kD form, myosin heads lay 
along the thick fi  lament backbone and were well ordered, 
but with the 130-kD form the myosin heads were ex-
tended and disordered.
In both intact and skinned cells, the 145-kD form can 
be converted completely to the 130-kD form by dephos-
phorylation of cMyBP-C, and the 130-kD form can be 
converted to the 145-kD form by phosphorylation with 
PKA. The 130-kD form in the in situ contracting heart 
and in vitro trabeculae can be converted to the 145-kD 
form by isoproterenol, which both raises intracellular Ca 
and phosphorylates cMyBP-C, and by rhythmic contrac-
tions. Even when contractile activity ceases, the 145-kD 
form persists as long as elevated extracellular Ca concen-
tration maintains phosphorylation. In in vitro cardiac 
muscle, contractile activity alone could not produce com-
plete phosphorylation of cMyBP-C, presumably because 
the slow rate of contraction did not raise intracellular Ca 
concentration suffi  ciently (Gautel et al., 1995; McClellan 
et al., 2001). The rate at which these transitions occur is 
suffi  ciently fast to modulate cardiac function but not on 
a beat-to-beat scale. The rate is consistent with the rate 
of phosphorylation and dephosphorylation of cMyBP-C 
(McClellan et al., 2001) and the rate of change in the 
structure of iso  lated thick fi  laments associated with phos-
phorylation (Weisberg and Winegrad, 1998).
Although the data show that a Ca-regulated phosphor-
ylation is necessary for the transition, they do not indi-
cate how much phosphorylation is required, whether it 
is one, two, or three phosphates per molecule of cMyBP-C. 
The data also do not distinguish between the consequence 
of multiple phosphates on a single molecule and mono-
phosphorylation of several molecules per thick fi  lament. 
These questions are currently being actively investigated 
Figure 9.  (A) Relation between cMyBP-C extracted and MHC 
lost. Each point represents the mean of at least four different ex-
periments. Lines between points are interpolations and do not 
represent a specifi  c function. (B) Western blots with anti C0C2 
(bottom) and anti-MHC (top). Lane 1, extraction solution for 4 h 
from skinned trabeculae; lane 2, relaxing solution for the next 
14 h from the same trabecula; lane 3, extraction solution for 4 h; 
lane 4, the extraction solution from the same trabecula for an 
additional 14 h.
Figure 10.  Left, electron micrographs of negatively stained, iso-
lated thick fi  laments with a normal content of cMyBP-C; right, fi  la-
ments from a trabecula that had had 36% of its cMyBP-C extracted. 
Both sets of fi  laments had been subjected to the same shear force 
of  17dynes/cm2. Note the intact thick fi  laments with central 
bare zones and tapered ends when cMyBP-C content is normal 
and the fragmented thick fi  laments where cMyBP-C had been 
extracted. Line indicates 1 μm. The magnification for the two 
micrographs is the same. The thinner images in the fragmented fi  l-
aments indicate that degradation of the thick fi  laments defi  cient in 
cMyBP-C is not simply a fracture through the entire fi  lament.426 Myosin-binding Protein C and Contractile Filament Turnover
in our laboratory. According to Moolman-Smook et al. 
(2002), three cMyBP-C molecules form a double-stranded 
collar around the thick fi  lament every 43 nm within 
the C zone. Removal of one molecule of cMyBP-C should 
leave a single-stranded collar, but loss of two molecules 
at a given locus would interrupt the integrity of the 
collar at that location. Loss of myosin from the thick 
fi  lament commences only after cMyBP-C content has 
been reduced by  20% as would be expected if the in-
tegrity of at least one ring of the collar is required for 
fi  lament stability.
The signifi  cance of the two forms of cMyBP-C and the 
transitions between them become clear when the mech-
anism of phosphorylation of cMyBP-C is considered. 
cMyBP-C has three phosphorylation sites, but a specifi  c 
one appears to require CAMK and to be phosphory-
lated fi  rst before the other two can be phosphorylated 
(Schlender and Bean, 1991; Gautel et al., 1995; McClellan 
et al., 2001). The concentration of Ca for Ca-sensitive 
phosphorylation of cMyBP-C is less than for activation 
of contraction, but higher than exists in a resting car-
diac cell bathed in normal extracellular concentration 
of Ca (McClellan et al., 2001). Therefore the resting 
cell should have a low level of phosphorylation of 
cMyBP-C, and respond weakly to PKA activation by β 
adrenergic agonists. Experimental results support both 
predictions (McClellan et al., 2001). Either elevated ex-
tracellular Ca or contraction at a rate in the physiologi-
cal range produces phosphorylation and permits further 
phosphorylation from β adrenergic stimulation.
The effect of Ca concentration on thick fi  lament deg-
radation in these studies appears to be very similar 
to the role of Ca in regulating myosin degradation in 
cultured neonatal cardiomyocytes (Bryon et al., 1996). 
In both studies, by a mechanism that does not require 
activation of contraction, raising extracellular Ca reduces 
myosin degradation. Raising Ca concentration increases 
phosphorylation of cMyBP-C (McClellan et al., 2001), 
which inhibits its proteolysis. The peptides produced by 
proteolysis in this study are stained by anti-C0C2 but not 
with anti-C5 or -C8C9, indicating that the cleavage has 
occurred in the C5C10 region. Proteolysis in this part of 
the cMyBP-C molecule should weaken interactions 
among the three cMyBP-C molecules and the rod por-
tion of myosin that are necessary for the formation of the 
putative cMyBP-C collar (Moolman-Smook et al., 2002). 
The result of proteolysis is dissociation of cMyBP-C, 
  release of MHC, and disassembly of the thick fi  lament 
(McClellan et al., 2004). The greater the amount of un-
phosphorylated cMyBP-C, the more rapidly MHC is lost 
and the thick fi  laments degraded under the conditions 
of our experiments. Apparently changes in phosphory-
lation at sites between C1 and C2 can modify the sensi-
tivity of the C5 to C10 region to proteolysis, perhaps by 
changing the folding of cMyBP-C in this region. Module 
C5 has a dynamic structure (Idowu et al., 2003), a prop-
erty that would facilitate the transfer of information be-
tween the C0C5 and the C5C10 collar. Since TNT remains 
bound to the myofi  brils, there is not corresponding 
degradation of thin fi  laments.
Although thick fi  laments defi  cient in cMyBP-C will 
degrade over time even in the absence of forces exerted 
on the fi  lament during contraction, loss of cMyBP-C 
makes the thick fi  lament more susceptible to fragmen-
tation when exposed to a shear force that intact fi  la-
ments can withstand and that may exist in parts of the 
normally contracting heart.
In cMyBP-C knockout (KO) mice, sarcomere struc-
ture has a normal appearance at low magnifi  cation and 
maximum Ca-activated force is not reduced, indicating 
that cMyBP-C is probably not required for thick fi  la-
ment stability in this preparation (Harris et al., 2002). 
The KO, in which cMyBP-C is absent from the embry-
onic state, can apparently compensate for the insta-
bility of thick fi   lament structure that appears when 
cMyBP-C is partially extracted from WT. To explain this 
difference or inconsistency in results with the different 
preparations and to elucidate the physiological and 
pathophysiological functions of cMyBP-C, studies with 
both types of preparations will be necessary.
Possible Physiological Functions
Several possible physiological functions for a mecha-
nism of the proposed type are suggested by published 
observations (Fig. 11). The dependence of both phos-
phorylation of cMyBP-C and the force of contraction 
on Ca concentration could form the basis for a mecha-
nism that could inversely couple the rate of degradation 
of thick fi   laments to the level of contractile force 
(Schlender and Bean, 1991; Gautel et al., 1995; Byron 
Figure 11.  Diagram showing our working hypothesis for in vivo 
function of the phosphorylation-dependent modulation of thick 
fi  lament stability. In vitro evidence for each of the steps has been 
presented in this study. Confi  rmation of a similar function in vivo 
will require further study.  Kulikovskaya et al. 427
et al., 1996; McClellan et al., 2001). The rate of degrada-
tion would decrease as the concentration of activating 
Ca rises and contractile force increases. The converse 
would also be true. Contractile activity, time-averaged 
intracellular Ca concentration, and phosphorylation of 
the second and third sites on cMyBP-C are all sensitive 
to adrenergic stimulation, making adrenergic activity a 
potentially important component in regulation of fi  la-
ment degradation. At this point the existence of this 
type of mechanism in intact hearts requires additional 
supporting evidence.
Although it is not clear whether turnover of the con-
tractile system occurs at the individual molecule or the 
individual fi  lament and whether damaged molecules or 
fi  laments are preferentially selected for turnover, de-
phosphorylation of cMyBP-C could be a marker for phys-
iological turnover. The transition between the 145- and 
the 130-kD forms can take place within minutes, suffi  -
ciently rapidly to modulate turnover.
There is evidence that dephosphorylation of cMyBP-C 
may contribute to myocardial dysfunction during myocar-
dial ischemia (Decker et al., 2005) and in heart failure 
(Paolocci, N., L. Tomiolo, I. Kulikovskaya, T. Katori, D.A. 
Kass, C. Reggiani, and S. Winegrad. 2006.   Biophys. J. 
90:274a). In ischemic hearts, dephosphorylation and 
proteolysis of cMyBP-C consistently and closely precede 
the decline in shortening of myocardial segments and the 
decrease in the number of myosin heads bound to thin 
fi  laments that occur during contraction. Dephosphory-
lation and proteolysis rise in parallel with the increase in 
end-diastolic pressure as hearts progress into failure from 
rapid pacing (Paolocci et al., 2006). Phosphorylation of 
cMyBP-C increases the ability of   intact hearts to tolerate a 
chronically increased load (Sadayappan et al., 2006).
It is clear that the role of cMyBP-C is complex and 
may involve several functions that appear different de-
pending on the nature of the preparation and the con-
ditions of the cardiac myocytes. A rigorous description 
of the physiological role of the proposed dephosphory-
lation-proteolysis mechanism will require further exper-
imentation with different preparations.
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